Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bank of Montreal (BMO) vs Nuwellis Inc (NUWE) Price & Performance

Bank of MontrealTrade
Nuwellis IncTrade

Price performance (Past 24H)

Key statistics

Bank of Montreal vs Nuwellis Inc — how do they compare? Bank of Montreal trades at $183.1 (market cap $125.53B), while Nuwellis Inc trades at $3.05 (market cap $1.17M). The key difference: Bank of Montreal is far larger — about 107290.6× Nuwellis Inc's market cap, and Bank of Montreal pays a 2.74% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.

BMONUWE
Market Cap
$125.53B$1.17M
Sector
FinancialsTechnology
52-Week High
$180.86$558.26
52-Week Low
$110.44$2.80
Dividend Yield
2.74%
Enterprise Value
-$636.97K

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bank of Montreal

BMO trades at $178.69, down 0.15% today, with a bullish technical signal supported by moving averages and key resistance at $180. The company reported strong Q1 2026 earnings of $2.68 per share, beating estimates, and maintains a solid net income margin of 25.92%. Recent acquisitions and dividend increases highlight strategic growth, while analyst sentiment is balanced with 44% buy ratings.

Outlook remains positive driven by consistent earnings beats and expansion in metals & mining banking. Risks include valuation above historical norms with a P/E of 19.48 and exposure to interest rate sensitivity. The stock offers a compelling dividend yield but faces macroeconomic headwinds that could pressure future performance.

Nuwellis Inc

NUWE trades at $2.80, down 7.89% in the last session, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025 despite $8.27M revenue, reflecting negative profit margins and cash flow challenges. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026, alongside a CEO transition to Mike McCormick effective June 30, 2026.

Outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is split evenly between Buy and Hold. Key risks include execution in revenue growth and reliance on financing. Upside depends on successful commercialization of Aquadex therapy and FDA label expansion for pediatric patients.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bank of Montreal

Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.

Read more on BMO

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE